相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis
Sabine Tacke et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2021)
Framework for personalized prediction of treatment response in relapsing remitting multiple sclerosis
E. Stuehler et al.
BMC MEDICAL RESEARCH METHODOLOGY (2020)
Differentiating societal costs of disability worsening in multiple sclerosis
Nils-Henning Ness et al.
JOURNAL OF NEUROLOGY (2020)
Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme
Jacqueline Palace et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2019)
Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis
M. Boremalm et al.
EUROPEAN JOURNAL OF NEUROLOGY (2019)
Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
Jens Kuhle et al.
NEUROLOGY (2019)
New drugs: where did we go wrong and what can we do better?
Beate Wieseler et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register
Damiano Paolicelli et al.
JOURNAL OF NEUROLOGY (2019)
Cladribine versus fingolimod, natalizumab and interferon for multiple sclerosis
Tomas Kalincik et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Cladribine versus fingolimod, natalizumab and interferon for multiple sclerosis
Tomas Kalincik et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry
Stefan Braune et al.
JOURNAL OF NEUROLOGY (2018)
Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis
Nathaniel Lizak et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2017)
New insights into the burden and costs of multiple sclerosis in Europe
Gisela Kobelt et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
New insights into the burden and costs of multiple sclerosis in Europe
Gisela Kobelt et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Guidelines for good pharmacoepidemiology practice (GPP)
Elizabeth B. Andrews et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2016)
Long-Term Evolution of Multiple Sclerosis Disability in the Treatment Era
Bruce A. C. Cree et al.
ANNALS OF NEUROLOGY (2016)
GetReal: from efficacy in clinical trials to relative effectiveness in the real world
Matthias Egger et al.
RESEARCH SYNTHESIS METHODS (2016)
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
Erik von Elm et al.
LANCET (2007)
Effect of relapses on development of residual deficit in multiple sclerosis
FD Lublin et al.
NEUROLOGY (2003)
分享论文
